One Capital Management LLC Cuts Position in Pfizer Inc. $PFE

Key Points

• One Capital Management LLC sharply reduced its Pfizer position in the fourth quarter, cutting holdings by 90.8% and selling 355,025 shares.
• Analysts remain cautious overall: Pfizer’s consensus rating is Hold, with an average price target of $28.82, even as a few firms upgraded or reiterated bullish views.
• Pfizer beat quarterly expectations with Q1 earnings of $0.75 per share on revenue of $14.45 billion, and it continues to offer a high dividend yield of about 6.8%.

One Capital Management LLC decreased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 90.8% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 35,812 shares of the biopharmaceutical company's stock after selling 355,025 shares during the period. One Capital Management LLC's holdings in Pfizer were worth $892,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. Triad Wealth Partners LLC raised its stake in shares of Pfizer by 1.9% during the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company's stock valued at $510,000 after purchasing an additional 386 shares during the period. ETF Store Inc. raised its stake in shares of Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company's stock valued at $272,000 after purchasing an additional 396 shares during the period. Mattern Wealth Management LLC raised its stake in shares of Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company's stock valued at $228,000 after purchasing an additional 400 shares during the period. Pines Wealth Management LLC raised its stake in shares of Pfizer by 4.4% during the fourth quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company's stock valued at $235,000 after purchasing an additional 400 shares during the period. Finally, Pathway Financial Advisers LLC raised its stake in shares of Pfizer by 0.9% during the fourth quarter. Pathway Financial Advisers LLC now owns 46,380 shares of the biopharmaceutical company's stock valued at $1,155,000 after purchasing an additional 403 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Daiwa Securities Group lowered shares of Pfizer from an "outperform" rating to a "neutral" rating and set a $27.00 price objective on the stock. in a research note on Thursday, February 12th. Bank of America dropped their price objective on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research note on Thursday, April 9th. Wolfe Research reiterated an "underperform" rating and set a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. Morgan Stanley raised their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an "equal weight" rating in a research report on Friday, April 10th. Finally, Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of "Hold" and an average target price of $28.82.

Pfizer Stock Performance

Shares of PFE opened at $25.37 on Thursday. Pfizer Inc. has a 1 year low of $23.08 and a 1 year high of $28.75. The company has a market cap of $144.57 billion, a price-to-earnings ratio of 19.36 and a beta of 0.34. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The firm has a fifty day moving average of $26.68 and a 200-day moving average of $26.29.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the company posted $0.92 earnings per share. The company's revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. Pfizer's payout ratio is 131.30%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s oncology pipeline drew renewed optimism after ASCO 2026 data showed encouraging Phase 3 results for BRAFTOVI in metastatic colorectal cancer and TALZENNA in prostate cancer, reinforcing the company’s long-term growth story. Pfizer Oncology Data At ASCO 2026 Reshapes Long Term Growth Story
• Positive Sentiment: Jefferies reiterated a buy rating on Pfizer, and another report highlighted Pfizer as undervalued, which may help support sentiment around the stock’s current valuation. Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
• Positive Sentiment: Pfizer also received coverage suggesting its obesity and oncology pipeline could deliver multiple catalysts in 2026, keeping investors focused on upcoming data readouts and regulatory events. Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
• Neutral Sentiment: Pfizer presented at the Jefferies Global Healthcare Conference, but the transcript appears to be mainly a routine investor update rather than a major new announcement. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Pfizer also announced updates on its ODEN ulcerative colitis study and completed a bevacizumab biosimilar safety study in Japan, both of which are incremental pipeline updates rather than immediate stock-moving breakthroughs. Pfizer’s ODEN Study Update: Real-World Data on Tofacitinib in Ulcerative Colitis
• Negative Sentiment: Some articles continue to frame Pfizer as a high-yield stock facing patent-cliff concerns and competitive comparisons with peers like Bristol Myers and Merck, which may weigh on sentiment despite the company’s pipeline progress. Bristol Myers vs. Pfizer: Which High-Yield Dividend Stock Wins Now?

Pfizer Company Profile

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.